LEIDEN, Netherlands, Sept. 13, 2024. Vico Therapeutics B.V., a clinical-stage genetic medicines company developing therapies for severe neurological...
Vous n'êtes pas connecté
- English
- Français
- عربي
- Español
- Deutsch
- Português
- русский язык
- Català
- Italiano
- Nederlands, Vlaams
- Norsk
- فارسی
- বাংলা
- اردو
- Azərbaycan dili
- Bahasa Indonesia
- Հայերեն
- Ελληνικά
- Bosanski jezik
- українська мова
- Íslenska
- Türkmen, Түркмен
- Türkçe
- Shqip
- Eesti keel
- magyar
- Қазақ тілі
- Kalaallisut ; kalaallit oqaasii
- Lietuvių kalba
- Latviešu valoda
- македонски јазик
- Монгол
- Bahasa Melayu ; بهاس ملايو
- ဗမာစာ
- Slovenščina
- тоҷикӣ ; toğikī ; تاجیکی
- ไทย
- O'zbek ; Ўзбек ; أۇزبېك
- Tiếng Việt
- ភាសាខ្មែរ
- རྫོང་ཁ
- Soomaaliga ; af Soomaali
Maroc - THEMARKETHERALD.CA - A La Une - 29/Aug 14:44
MindBio advances world-first psychedelic microdosing clinical trials
MindBio Therapeutics (CSE:MBIO) announces the successful completion of its Phase 1 and 2a clinical trials on depression treatment.
Articles similaires
Iron Deficiency Anemia Market Analysis 2034 | Iron Deficiency Anemia Therapies, Clinical trials, Iron Deficiency Anemia prevalence, Treatment Algorithms | Akebia Therapeutics, Shield Therapeutics
mountaintoday.in - 04/Sep 08:17
Iron Deficiency Anemia Market As per DelveInsight, the Iron Deficiency Anemia Market is anticipated to grow immensely in the coming years owing to the...
Iron Deficiency Anemia Market Analysis 2034 | Iron Deficiency Anemia Therapies, Clinical trials, Iron Deficiency Anemia prevalence, Treatment Algorithms | Akebia Therapeutics, Shield Therapeutics
mountaintoday.in - 04/Sep 08:17
Iron Deficiency Anemia Market As per DelveInsight, the Iron Deficiency Anemia Market is anticipated to grow immensely in the coming years owing to the...
In a First-of-its-kind Fixed Dose Study, Once Weekly Insulin Efsitora Alfa Leads to A1C Reduction Similar to Daily Insulin
drugs.com - 05/Sep 06:09
INDIANAPOLIS, Sept. 5, 2024 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced positive topline results from the QWINT-1 and QWINT-3...
In a First-of-its-kind Fixed Dose Study, Once Weekly Insulin Efsitora Alfa Leads to A1C Reduction Similar to Daily Insulin
drugs.com - 05/Sep 06:09
INDIANAPOLIS, Sept. 5, 2024 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced positive topline results from the QWINT-1 and QWINT-3...
Clinical Pharmacist – Operations Manager at IQVIA
jobwebkenya.com - 11/Sep 19:05
IQVIA, formerly Quintiles and IMS Health, Inc.,is an American multinational company serving the combined industries of health information technology...
Recursion Announces Phase 2 Data of REC-994, a First-in-Disease Investigational Treatment for Symptomatic Cerebral Cavernous Malformation (CCM), has Met its Primary Endpoint of Safety and Tolerability
qatarnewswire.qa - 03/Sep 12:17
REC-994 also demonstrates encouraging trends in objective MRI-based exploratory efficacy measures at the highest dose and the company plans to advance...
Recursion Announces Phase 2 Data of REC-994, a First-in-Disease Investigational Treatment for Symptomatic Cerebral Cavernous Malformation (CCM), has Met its Primary Endpoint of Safety and Tolerability
qatarnewswire.qa - 03/Sep 12:17
REC-994 also demonstrates encouraging trends in objective MRI-based exploratory efficacy measures at the highest dose and the company plans to advance...
Recursion Announces Phase 2 Data of REC-994, a First-in-Disease Investigational Treatment for Symptomatic Cerebral Cavernous Malformation (CCM), has Met its Primary Endpoint of Safety and Tolerability
menafocus.qa - 03/Sep 12:17
REC-994 also demonstrates encouraging trends in objective MRI-based exploratory efficacy measures at the highest dose and the company plans to advance...
Recursion Announces Phase 2 Data of REC-994, a First-in-Disease Investigational Treatment for Symptomatic Cerebral Cavernous Malformation (CCM), has Met its Primary Endpoint of Safety and Tolerability
pressarabia.qa - 03/Sep 12:17
REC-994 also demonstrates encouraging trends in objective MRI-based exploratory efficacy measures at the highest dose and the company plans to advance...
Les derniers communiqués
-
Four Seasons to Expand Saudi Arabian Portfolio Alongside Dar Al Omran Company with New Hotel in Madinah
Four Seasons Hotels and Resorts - 07/05/2024
-
Four Seasons Yachts Unveils Inaugural Itineraries to the Caribbean and Mediterranean and a First Look at its 95 Spectacular Suites
Four Seasons Hotels and Resorts - 27/03/2024
-
Visual 01Elevating Excellence: Four Seasons Embarks on the Next Stage of Strategic Global Growth
Four Seasons Hotels and Resorts - 22/01/2024